Truist Securities analyst Danielle Brill reiterated a Hold rating and $23.00 price target on Immunovant (NASDAQ: IMVT)The analyst commented, "IMVT’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE